复方阿胶浆联合XELOX方案治疗晚期胃癌的临床观察

目的 观察复方阿胶浆联合奥沙利铂与希罗达（XELOX方案）治疗晚期胃癌的临床疗效及对化疗的增效减毒作用.方法 将60例晚期胃癌患者分为治疗组与对照组,治疗组接受复方阿胶浆联合XELOX方案化疗,对照组仅接受XELOX方案化疗,观察2组临床疗效及不良反应情况.结果 治疗后2组患者症状均改善,治疗组较对照组改善更明显;治疗组与对照组卡氏评分总有效率分别为100%,83%,2组比较有显著性差异（P〈0.05）.治疗组与对照组总有效率分别为17%,10%,2组比较无显著性差异;治疗组的化疗不良反应（白细胞减少、贫血、消化道反应及手足综合征）发生率明显低于对照组（P〈0.05）;治疗组治疗后CD3＋、CD4＋、CD4＋/CD8＋较治疗前及对照组均升高（P均〈0.05）.结论 复方阿胶浆联合XELOX方案化疗治疗晚期胃癌,可提高机体免疫力,减轻化疗不良反应,改善生活质量.

Clinical observation on advanced gastric cancer treated by combination of compound ass-hide slurry and XELOX regimen

Objective It is to observe the clinical effect of compound asshide slurry （CAS） combined with Oxaliplatin and Xeloda （XELOX） regimen in treatment of advanced gastric cancer and it＇ s synergism and attenuation to chemotherapy. Methods 60 patients with advanced gastric cancer were randomly divided into two groups, and treated with CAS plus XELOX regimen in treatment group and with single XELOX regimen in control group. The clinical effect and adverse reaction were ob served in two groups. Results After treatment, the symptom was improved in both groups. The score of KPS was 100% in treatment group and 83% in control group, there was significant difference （P 〈 0.05）. The total effective rate was 17% in treatment group and 10% in control group, there was no significant difference （P 〉 0.05）. The occurrence rate of adverse re actions （include leucopenia, anaemia, enteron side effect and handfoot syndrome） of treatment group was markedly decreased than that of control group （P 〈 0.05 ）. The levels of CD3 , CD4 and CD4 /CD8 in treatment group were improved com pared with pretreatment and control group （ all P 〈 0.05 ）. Conclusion CAS combined with XELOX regimen for advanced gastric cancer can markedly improve the immunity of the body; it also can reduce the incidence of adverse reactions of chemo therapy and improve the quality of life of patients.